DNA methylation in haematological malignancies: the role of decitabine

Bibliography

• MOMPARLER RL, BOVENZI V: DNA methylation and cancer. J. Cell Physiol. (2000) 183:145–154.
   PubMed Web of Science ®Google Scholar
• BAYLIN SB, HERMAN JG, GRAFF JR et al.: Alterations in DNA methylation: a fundamental aspect of neoplasia. Adv. Cancer Res. (1998) 72:141–196.
   PubMed Web of Science ®Google Scholar
• ••DNA methylation is an importantepigenetic modification in oncogenesis.
   Google Scholar
• GILES FJ: New drugs in acute myeloid leukemia. Curc Oncol. Rep. (2002) 4:369–374.
   PubMedGoogle Scholar
• YEIVIN A, RAZIN A: Gene methylationpatterns and expression. EXS (1993) 64:523–568.
   PubMedGoogle Scholar
• BEARZATTO A, SZADKOWSKI M, MacPHERSON P et al.: Epigenetic regulation of the MGMT and hMSH6 DNA repair genes in cells resistant to methylating agents. Cancer Res. (2000) 60:3262–3270.
   PubMed Web of Science ®Google Scholar
• VAN DEN WYNGAERT I, ADAMS RL,KASS SU: In vitro methylation of predetermined regions in recombinant DNA constructs. Methods Mol. Biol. (2001) 181:243–250.
   PubMedGoogle Scholar
• KASS SU, PRUSS D, WOLFFE AP: Howdoes DNA methylation repress transcription? Trends Genet. (1997) 13:444–449.
   Google Scholar
• BHATTACHARYA SK, RAMCHANDANI S, CERVONI N et al: A mammalian protein with specific demethylase activity for mCpG DNA. Nature (1999) 397:579–583.
   PubMed Web of Science ®Google Scholar
• HAMEL PA, HANLEY-HYDE J: G1 cyclins and control of the cell division cycle in normal and transformed cells. Cancer Invest. (1997) 15:143–152.
   PubMed Web of Science ®Google Scholar
• CHANG LL, YEH WT, YANG SY et al: Genetic alterations of pl6INK4a and p14ARF genes in human bladder cancer. Urol. (2003) 170:595–600.
   Web of Science ®Google Scholar
• TYLER LN, AT L, ZUO C et al.: Analysis of promoter hypermethylation of death-associated protein kinase and p16 tumor suppressor genes in actinic keratoses and squamous cell carcinomas of the skin. Mod. Pathol. (2003) 16:660–664.
   PubMed Web of Science ®Google Scholar
• SANZ-CASLA MT, MAESTRO ML, DEL BARCO V et al.: Loss of heterozygosity and methylation of p16 in renal cell carcinoma. Urol. Res. (2003) 31:159–162.
   Google Scholar
• TANG S, LUO H, YU J et a/.: Relationship between alterations of p16(INK4a) and p14(ARF) genes of CDKN2A locus and gastric carcinogenesis. ChM. Med. (Engl.) (2003) 116:1083–1087.
   Google Scholar
• WENMING C, JIAZHI Z, SHUZHEN T et al.: Inactivation of p16 gene in leukemia. ChM. Med. Sci. (1999) 14:206–210.
   PubMedGoogle Scholar
• UEHARA E, TAKEUCHI S, TASAKA T et al.: Aberrant methylation in promoter-associated CpG islands of multiple genes in therapy-related leukemia. Int. J. Oncol (2003) 23:693–696.
   PubMed Web of Science ®Google Scholar
• CHIM CS, WONG SY, KWONG YL: Aberrant gene promoter methylation in acute promyelocytic leukaemia: profile and prognostic significance. Br. Haematol (2003) 122:571–578.
   PubMed Web of Science ®Google Scholar
• ••Gene promoter methylation abnormalitiesare important in acute promyelocytic leukemia.
   Google Scholar
• WANG C, LU X: [Alterations of the p16 gene for the carcinogenesis in pancreas]. Zhongguo Yi Xue Ke Xue Yuan Xue Bao (2000) 22:491–493.
   PubMedGoogle Scholar
• CHEN W, WU Y, ZHU J et al: Methylation of p16 and p15 genes in multiple myeloma. ChM. Med. Sci. (2002) 17:101–105.
   PubMedGoogle Scholar
• YANAGAWA N, TAMURA G, OIZUMI H et al: Promoter hypermethylation of tumor suppressor and tumor-related genes in non-small cell lung cancers. Cancer Sci. (2003) 94:589–592.
   PubMed Web of Science ®Google Scholar
• HERMAN JG, MERLO A, MAO L et al.: Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res. (1995) 55:4525–4530.
   PubMed Web of Science ®Google Scholar
• GUO SX, TAKI T, OHNISHI H et al: Hypermethylation of p16 and p15 genes and RB protein expression in acute leukemia. Leak. Res. (2000) 24:39–46.
   PubMed Web of Science ®Google Scholar
• QUESNEL B, FENAUX P: pl5INK4b gene methylation and myelodysplastic syndromes. Leak. Lymphoma (1999) 35:437–443.
   PubMed Web of Science ®Google Scholar
• BAEZA N, WELLER M, YONEKAWA Y et al.: PTEN methylation and expression in glioblastomas. Acta Neuropathol (Berl) (2003) 106(5):479–485.
   PubMed Web of Science ®Google Scholar
• SATO N, FUKUSHIMA N, MAEHARA N et al.: SPARC/osteonectin is a frequent target for aberrant methylation in pancreatic adenocarcinoma and a mediator of tumor-stromal interactions. Oncogene (2003) 22:5021–5030.
   PubMed Web of Science ®Google Scholar
• SATHYANARAYANA UG, TOYOOKA S, PADAR A et al.: Epigenetic inactivation of laminin-5-encoding genes in lung cancers. Gin. Cancer Res. (2003) 9:2665–2672.
   Web of Science ®Google Scholar
• FUKUSHIMA N, SATO N, SAHIN F et al.: Aberrant methylation of suppressor of cytokine signalling-1 (SOCS-1) gene in pancreatic ductal neoplasms. Br. Cancer (2003) 89:338–343.
   Web of Science ®Google Scholar
• KONDURI SD, SRI VENUGOPAL KS, YANAMANDRA N et al.: Promoter methylation and silencing of the tissue factor pathway inhibitor-2 (TFPI-2), a gene encoding an inhibitor of matrix metalloproteinases in human glioma cells. Oncogene (2003) 22:4509–4516.
   Google Scholar
• LU GL, WEN JM, XU JM et al: [Relationship between TIMP-3 expression and promoter methylation of TIMP-3 gene in hepatocellular carcinoma]. Zhonghua Bing Li Xue Za Zhi (2003) 32:230–233.
   PubMedGoogle Scholar
• NISHIMURA M, SAITO T, YAMASAKI H et al: Suppression of gap junctional intercellular communication via 5' CpG island methylation in promoter region of E-cadherin gene in endometrial cancer cells. Carcinogenesis (2003) 24(10):1615–1623
   PubMed Web of Science ®Google Scholar
• GRAFF JR, HERMAN JG, LAPIDUS RG et al.: E-cadherin expression is silenced by DNA hypermethylation in human breast and prostate carcinomas. Cancer Res. (1995) 55:5195–5199.
   PubMed Web of Science ®Google Scholar
• LI Q, AHUJA N, BURGER PC et al: Methylation and silencing of the thrombospondin-1 promoter in human cancer. Oncogene (1999) 18:3284–3289.
   PubMed Web of Science ®Google Scholar
• TOYOTA M, KOPECKY KJ, TOYOTA MO et al.: Methylation profiling in acute myeloid leukemia. Blood (2001) 97:2823–2829.
   PubMed Web of Science ®Google Scholar
• ••Methylation profiling is possible and ofvalue in AML.
   Google Scholar
• YAMANAKA M, WATANABE M, YAMADA Y et al.: Altered methylation of multiple genes in carcinogenesis of the prostate. Int.j Cancer (2003) 106:382–387.
   PubMed Web of Science ®Google Scholar
• KUROKI T, TRAPASSO F, YENDAMURI S et al.: Allele loss and promoter hypermethylation of VHL, RAR-beta, RASSF1A, and FHIT tumor suppressor genes on chromosome 3p in esophageal squamous cell carcinoma. Cancer Res. (2003) 63:3724–3728.
   PubMed Web of Science ®Google Scholar
• ISSA JP: Methylation and prognosis: of molecular clocks and hypermethylator phenotypes. Clin. Cancer Res. (2003) 9:2879–2881.
   PubMedGoogle Scholar
• GARCIA-MANERO G, DANIEL J, SMITH TL et al.: DNA methylation of multiple promoter-associated CpG islands in adult acute lymphocytic leukemia. Clin. Cancer. Res. (2002) 8:2217-2224. Methylation profile of adult ALL.
   Google Scholar
• CHANG TS, KIM MJ, RY00 K et al: p57KIP2 modulates stress-activated signaling by inhibiting c-Jun NH2-terminal kinase/stress-activated protein kinase. Biol. Chem. (2003) (in press).
   Google Scholar
• SHEN L, TOYOTA M, KONDO Y et al: Aberrant DNA methylation of p571cip2 identifies a cell cycle regulatory pathway with prognostic impact in adult acute lymphocytic leukemia. Blood (2003) 101(10):4131–4136.
   PubMed Web of Science ®Google Scholar
• GARCIA-MANERO G, JEHA S, DANIEL J et al.: Aberrant DNA methylation in pediatric patients with acute lymphocytic leukemia. Cancer (2003) 97:695–702.
   PubMed Web of Science ®Google Scholar
• ••Methylation profile in paediatric ALL.
   Google Scholar
• MIZUNO S, CHIJIWA T, OKAMURA T et al.: Expression of DNA methyltransferases DNMT1, 3A, and 3B in normal hematopoiesis and in acute and chronic myelogenous leukemia. Blood (2001) 97:1172–1179.
   PubMed Web of Science ®Google Scholar
• KIM DH, KIM JS, JI YI et al: Hypermethylation of RASSF1A promoter is associated with the age at starting smoking and a poor prognosis in primary non-small cell lung cancer. Cancer Res. (2003) 63:3743–3746.
   PubMed Web of Science ®Google Scholar
• NIITSU N, HAYASHI Y, SUGITA K et al.: Sensitization by 5-aza-2'-deoxycytidine of leukaemia cells with MLL abnormalities to induction of differentiation by all-trans retinoic acid and 1 alpha,25-dihydroxyvitamin D3. Br. .1. Haematol (2001) 112:315–326.
   Google Scholar
• TAYLOR SM, JONES PA: Multiple new phenotypes induced in 10T1/2 and 3T3 cells treated with 5-azacytidine. Cell (1979) 17:771–779.
   PubMed Web of Science ®Google Scholar
• ••Differentiation abilities of 5-azacytidine.
   Google Scholar
• JONES PA, TAYLOR SM: Cellular differentiation, cytidine analogs and DNA methylation. Cell (1980) 20:85–93.
   PubMed Web of Science ®Google Scholar
• MOMPARLER RL, BOUCHARD J, SAMSON J: Induction of differentiation and inhibition of DNA methylation in HL-60 myeloid leukemic cells by 5-AZA-2'-deoxycytidine. Leak. Res. (1985) 9:1361–1366.
   PubMed Web of Science ®Google Scholar
• CREUSOT F, ACS G, CHRISTMAN JK:Inhibition of DNA methyltransferase and induction of Friend erythroleukemia cell differentiation by 5-azacytidine and 5-aza-2'-deoxycytidine. I Biol. Chem. (1982) 257:2041–2048.
   Web of Science ®Google Scholar
• LAVELLE D, DESIM ONE J, HANKEWYCH M et al: Decitabine induces cell cycle arrest at the G1 phase via p21(WAF1) and the G2/M phase via the p38 MAP kinase pathway. Leak. Res. (2003) 27:999–1007.
   PubMed Web of Science ®Google Scholar
• SUH SI, PYUN HY, CHO JVV et al: 5-Aza-2'-deoxycytidine leads to down-regulation of aberrant p16INK4A RNA transcripts and restores the functional retinoblastoma protein pathway in hepatocellular carcinoma cell lines. Cancer Lett. (2000) 160:81–88.
   PubMed Web of Science ®Google Scholar
• MOMPARLER RL, MOMPARLER LF, SAMSON J: Comparison of the antileukemic activity of 5-AZA-2'-deoxycytidine, 1-beta-D-arabinofuranosylcytosine and 5-azacytidine against L1210 leukemia. Leak. Res. (1984) 8:1043–1049.
   PubMed Web of Science ®Google Scholar
• COVEY JM, ZAHARKO DS: Effects ofdose and duration of exposure on 5-aza-2'-deoxycytidine cytotoxicity for L1210 leukemia in vitro. Cancer Treat Rep. (1984) 68:1475–1481.
   PubMedGoogle Scholar
• DASKALAKIS M, NGUYEN TT, NGUYEN C et al.: Demethylation of a hypermethylated P15/INK4B gene in patients with myelodysplastic syndrome by 5-aza-2'-deoxycytidine (decitabine) treatment. Blood(2002) 100:2957–2964.
   PubMed Web of Science ®Google Scholar
• YANG Q, SHAN L, YOSHIMURA G et al.: 5-Aza-2'-deoxycytidine induces retinoic acid receptor beta 2 demethylation, cell cycle arrest and growth inhibition in breast carcinoma cells. Anticancer Res. (2002) 22:2753–2756.
   PubMed Web of Science ®Google Scholar
• FULDA S, KUFER MU, MEYER E et al.:Sensitization for death receptor- or drug-induced apoptosis by re-expression of caspase-8 through demethylation or gene transfer. Oncogene (2001) 20:5865–5877.
   PubMed Web of Science ®Google Scholar
• SERRANO A, TANZARELLA S, LIONELLO I et al.: Rexpression of HLA class I antigens and restoration of antigen-specific CTL response in melanoma cells following 5-aza-2'-deoxycytidine treatment. Cancer (2001) 94:243–251.
   Web of Science ®Google Scholar
• VENKATASUBBARAO K, AMMANAMANCHI S, BRATTAIN MG et al.: Reversion of transcriptional repression of Spl by 5 aza-2' deoxycytidine restores TGF-beta Type II receptor expression in the pancreatic cancer cell line MIA PaCa-2. Cancer Res. (2001) 61:6239–6247.
   PubMed Web of Science ®Google Scholar
• SIEDOW A, SZYF M, GRATCHEV A et al.: Be novo expression of the Muc2 gene in pancreas carcinoma cells is triggered by promoter demethylation. Tumour Biol. (2002) 23:54–60.
   PubMed Web of Science ®Google Scholar
• HARTS OUGH MT, CLARE SE, MAIR Met al.: Elevation of breast carcinoma Nm23-H1 metastasis suppressor gene expression and reduced motility by DNA methylation inhibition. Cancer Res. (2001) 61:2320–2327.
   Google Scholar
• PLUMB JA, STRATHDEE G, SLUDDEN J et al: Reversal of drug resistance in human tumor xenografts by 2'-deoxy-5-azacytidine-induced demethylation of the hMLH1 gene promoter. Cancer Res. (2000) 60:6039–6044.
   PubMed Web of Science ®Google Scholar
• [NO AUTHORS LISTED]: Decitabine: 2'-deoxy-5-azacytidine, Aza dC, DAC, dezocitidine, NSC 127716. Drugs RD (2003) 4:179–184.
   PubMedGoogle Scholar
• RIVARD GE, MOMPARLER RL, DEMERS J et al.: Phase I study on 5-aza-2'-deoxycytidine in children with acute leukemia. Leak. Res. (1981) 5:453–462.
   PubMed Web of Science ®Google Scholar
• ••Decitabine phase I study in paediatricleukemia.
   Google Scholar
• MOMPARLER RL, RIVARD GE, GYGER M: Clinical trial on 5-aza-2'-deoxycytidine in patients with acute leukemia. Pharmacol Ther. (1985) 30:277–286.
   PubMed Web of Science ®Google Scholar
• LUBBERT M, WIJERMANS P, KUNZMANN R et al.: Cytogenetic responses in high-risk myelodysplastic syndrome following low-dose treatment with the DNA methylation inhibitor 5-aza-2'-deoxycytidine. Br. J. Haematol (2001) 114:349–357.
   PubMed Web of Science ®Google Scholar
• RAVANDI F, KANTARJIAN H, COHEN A et al.: Decitabine with allogeneic peripheral blood stem cell transplantation in the therapy of leukemia relapse following a prior transplant: results of a Phase I study. Bone Marrow Transplant. (2001) 27:1221–1225.
   PubMed Web of Science ®Google Scholar
• DE LIMA M, RAVANDI F, SHAHJAHAN M et al.: Long-term follow-up of a Phase I study of high-dose decitabine, busulfan, and cyclophosphamide plus allogeneic transplantation for the treatment of patients with leukemias. Cancer (2003) 97:1242–1247.
   PubMed Web of Science ®Google Scholar
• SACCHI S, KANTARJIAN HM, O'BRIEN S et al: Chronic myelogenous leukemia in nonlymphoid blastic phase: analysis of the results of first salvage therapy with three different treatment approaches for 162 patients. Cancer (1999) 86:2632–2641.
   PubMed Web of Science ®Google Scholar
• GARCIA-MANERO G, FADERL S, O'BRIEN S et al.: Chronic myelogenous leukemia: a review and update of therapeutic strategies. Cancer (2003) 98:437–457.
   Google Scholar
• PINTO A, ZAGONEL V, ATTADIA V et al.: 5-Aza-2'-deoxycytidine as a differentiation inducer in acute myeloid leukaemias and myelodysplastic syndromes of the elderly. Bone Marrow Transplant. (1989) 3\(Supp1.4):28–32.
   Google Scholar
• WIJERMANS P, LUBBERT M, VERHOEF G et al: Low-dose 5-aza-2'-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter Phase II study in elderly patients. Oncol (2000) 18:956–962.
   Google Scholar
• WIJERMANS PW, LUEBBERT M, VERHOEF G: Low dose decitabine for elderly high risk MDS patients: who will respond? Blood(2002) 100 (Abstract 96).
   Google Scholar
• KANTARJIAN HM, O'BRIEN S, CORTES J et al.: Results of decitabine (5-aza-2'deoxycytidine) therapy in 130 patients with chronic myelogenous leukemia. Cancer (2003) 98:522–528.
   Google Scholar
• ••Decitabine has significant anti-CMLactivity.
   Google Scholar
• ISSA JP, GARCIA-MANERO G, MANNARI M et al.: Minimal effective dose of hypomethylating agent decitabine in hematopoietic malignancies. Blood (2001) 98 (Abstract 594).
   Google Scholar
• ZHU WG, LAKSHMANAN RR, BEAL MD et al.: DNA methyltransferase inhibition enhances apoptosis induced by histone deacetylase inhibitors. Cancer Res. (2001) 61:1327–1333.
   PubMed Web of Science ®Google Scholar
• ROBERTSON KD, WOLFFE AP: DNA methylation in health and disease. Nat. Rev. Genet. (2000) 1:11–19.
   PubMed Web of Science ®Google Scholar